Syndax Pharmaceuticals, Inc.
SNDX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $2 | $2 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $1 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 96.5% | – | – | 100% |
| EBITDA | -$0 | -$0 | -$0 | $0 |
| % Margin | -1,325.3% | – | – | 19.2% |
| Net Income | -$0 | -$0 | -$0 | $0 |
| % Margin | -1,346.1% | – | – | 17.8% |
| EPS Diluted | -3.73 | -2.98 | -2.46 | 0.48 |
| % Growth | -25.2% | -21.1% | -612.5% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | $0 |
| Capital Expenditures | $0 | $0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | $0 |